RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Pacific Biosciences of California Stock

Pacific Biosciences of California P/E 2024

Pacific Biosciences of California P/E

-1.86

Ticker

PACB

ISIN

US69404D1081

WKN

A1C3EQ

As of Jul 16, 2024, Pacific Biosciences of California's P/E ratio was -1.86, a -82.5% change from the -10.63 P/E ratio recorded in the previous year.

The Pacific Biosciences of California P/E history

Pacific Biosciences of California Aktienanalyse

What does Pacific Biosciences of California do?

Pacific Biosciences of California Inc is an American biotechnology company specializing in the development of systems for DNA sequencing and genome research. The company was founded in 2004 and is headquartered in Menlo Park, California. The company was founded by biochemist Stephen Turner, who had previously worked at Illumina, a leading company in genome research. The goal was to develop a new technology for DNA sequencing that would be faster and more accurate than existing systems. In 2005, the company received investments from notable venture capitalists such as Mohr Davidow Ventures, Alloy Ventures, and Kleiner Perkins Caufield & Byers. In 2010, Pacific Biosciences released its first commercial DNA sequencing system. The business model of Pacific Biosciences is based on the development and marketing of DNA sequencing systems and related products and services. The company offers standalone devices as well as integrated solutions for genome research to its customers, including research and diagnostic laboratories. Pacific Biosciences focuses on long-term customer relationships and the continuous advancement of its technologies. Pacific Biosciences operates in two main business segments: research and diagnostics. In the research segment, the company offers DNA sequencing systems that help researchers decipher the DNA of individual cells and complex genomes. These systems enable scientists to deepen their understanding of molecular-level biological processes and diseases. In the diagnostics segment, Pacific Biosciences develops solutions for personalized medicine and application in clinical laboratories. The main product of Pacific Biosciences is the PacBio RS II DNA sequencing platform. This system is based on the single-molecule sequencing technology, which offers high accuracy and reading speed. The PacBio RS II is a fully integrated device that performs both DNA preparation and sequencing, simplifying the entire workflow. In addition, Pacific Biosciences also offers a variety of products and services tailored to the needs of its customers. These include DNA extraction kits, sequencing software, and analysis tools. In summary, Pacific Biosciences of California is a biotechnology company specializing in the development of systems for DNA sequencing and genome research. Founded in 2004, the company is headquartered in Menlo Park, California. Pacific Biosciences operates in two main business segments, research and diagnostics, and offers a variety of products and services tailored to the needs of its customers. The main product of Pacific Biosciences is the PacBio RS II DNA sequencing platform, based on single-molecule sequencing technology. Pacific Biosciences of California ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Pacific Biosciences of California's P/E Ratio

The Price to Earnings (P/E) Ratio of Pacific Biosciences of California is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Pacific Biosciences of California's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Pacific Biosciences of California is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Pacific Biosciences of California’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Pacific Biosciences of California stock

What is the price-to-earnings ratio of Pacific Biosciences of California?

The price-earnings ratio of Pacific Biosciences of California is currently -1.86.

How has the price-earnings ratio of Pacific Biosciences of California changed compared to last year?

The price-to-earnings ratio of Pacific Biosciences of California has increased by -82.5% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Pacific Biosciences of California high compared to other companies?

Yes, the price-to-earnings ratio of Pacific Biosciences of California is high compared to other companies.

How does an increase in the price-earnings ratio of Pacific Biosciences of California affect the company?

An increase in the price-earnings ratio of Pacific Biosciences of California would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Pacific Biosciences of California affect the company?

A decrease in the price-earnings ratio of Pacific Biosciences of California would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Pacific Biosciences of California?

Some factors that influence the price-earnings ratio of Pacific Biosciences of California are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Pacific Biosciences of California pay?

Over the past 12 months, Pacific Biosciences of California paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Pacific Biosciences of California is expected to pay a dividend of 0 USD.

What is the dividend yield of Pacific Biosciences of California?

The current dividend yield of Pacific Biosciences of California is .

When does Pacific Biosciences of California pay dividends?

Pacific Biosciences of California pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Pacific Biosciences of California?

Pacific Biosciences of California paid dividends every year for the past 0 years.

What is the dividend of Pacific Biosciences of California?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Pacific Biosciences of California located?

Pacific Biosciences of California is assigned to the 'Health' sector.

Wann musste ich die Aktien von Pacific Biosciences of California kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Pacific Biosciences of California from 7/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/16/2024.

When did Pacific Biosciences of California pay the last dividend?

The last dividend was paid out on 7/16/2024.

What was the dividend of Pacific Biosciences of California in the year 2023?

In the year 2023, Pacific Biosciences of California distributed 0 USD as dividends.

In which currency does Pacific Biosciences of California pay out the dividend?

The dividends of Pacific Biosciences of California are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Pacific Biosciences of California stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Pacific Biosciences of California

Our stock analysis for Pacific Biosciences of California Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pacific Biosciences of California Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.